Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$355.2MCash on Hand
CF+ Cash Runway
Follow CRMD by emailGet an email when CRMD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CRMD, unsubscribe in one click. Privacy
📣 What CRMD Says Is Next
first quarter of 2027 · “CorMedix believes the transaction will be immediately accretive to earnings and free cash flow upon closing, which it anticipates in the first quarter of 2027, subject to approval by Heron’s stockholders, regulatory clearance and other customary closing conditions.”
Company press release, Nov 12, 2026 · SEC filing
Q1 2027 · “The sNDA was submitted by Mundipharma, CorMedix’s global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027.”
Company press release, Oct 19, 2026 · SEC filing
2H26 · “The companies anticipate a pre-NDA submission meeting with FDA in the coming months, followed by a target submission of a supplemental New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results.”
Company press release, Apr 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings CorMedix furnished the transcript of its Q3 2026 earnings call, reporting consolidated revenue of $54.5 million, adjusted EBITDA of $3.1 million and $355 million in cash, and narrowing full-year 2026 adjusted EBITDA guidance to $130 million to $140 million. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Deal CorMedix reported Q3 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, with adjusted EBITDA of $3.1 million. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 10, 2026 ·
Deal CorMedix agreed to acquire substantially all assets of Heron Therapeutics under a definitive asset purchase agreement, adding ZYNRELEF, APONVIE, CINVANTI and SUSTOL with about $150 million in trailing 12 months net product revenue. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Deal Entered an asset purchase agreement to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash, subject to adjustments, plus 14,583,333 shares of common stock. Earn-outs of up to $55 million and a 5% royalty are contingent. Form 8-K · SEC filing · Press release
Nov 2, 2026 ·
Earnings Reported unaudited cash and equivalents of about $355 million as of September 30, 2026, reaffirmed 2026 total revenue guidance of $325 million to $345 million, and said CMS set the Q1 2027 DefenCath Add-on at $8.32 per session. Form 8-K · SEC filing · Press release
Oct 19, 2026 ·
Regulatory FDA accepted for filing the sNDA for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease, with Priority Review and a PDUFA target action date in Q1 2027. Promotional efforts are targeted to begin in H2 2027 if approved. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 consolidated revenue of $101.9 million, net income of $26.0 million and adjusted EBITDA of $58.7 million. Maintains FY 2026 revenue guidance of $325 to $345 million and raises adjusted EBITDA guidance to $125 to $140 million. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2028 · Phase 3 · Recruiting · Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central… Registry primary completion date, not a results date
Jul 2028 · Phase 4 · Recruiting · Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not CRMD's own candidates): Deferiprone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CRMD holds $355.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 79,537,626 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CRMD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRMD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.